Background
In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation.
Methods
This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. Those trial participants with hypoxia (oxygen saturation <92% on air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein ≥75 mg/L) were eligible for random assignment in a 1:1 ratio to usual standard of care alone versus usual standard of care plus tocilizumab at a dose of 400 mg–800 mg (depending on weight) given intravenously. A second dose could be given 12–24 h later if the patient's condition had not improved. The primary outcome was 28-day mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN (50189673) and
ClinicalTrials.gov
(
NCT04381936
).
Findings
Between April 23, 2020, and Jan 24, 2021, 4116 adults of 21 550 patients enrolled into the RECOVERY trial were included in the assessment of tocilizumab, including 3385 (82%) patients receiving systemic corticosteroids. Overall, 621 (31%) of the 2022 patients allocated tocilizumab and 729 (35%) of the 2094 patients allocated to usual care died within 28 days (rate ratio 0·85; 95% CI 0·76–0·94; p=0·0028). Consistent results were seen in all prespecified subgroups of patients, including those receiving systemic corticosteroids. Patients allocated to tocilizumab were more likely to be discharged from hospital within 28 days (57%
vs
50%; rate ratio 1·22; 1·12–1·33; p<0·0001). Among those not receiving invasive mechanical ventilation at baseline, patients allocated tocilizumab were less likely to reach the composite endpoint of invasive mechanical ventilation or death (35%
vs
42%; risk ratio 0·84; 95% CI 0·77–0·92; p<0·0001).
Interpretation
In hospitalised COVID-19 patients with hypoxia and systemic inflammation, tocilizumab improved survival and other clinical outcomes. These benefits were seen regardless of the amount of respiratory support and were additional to the benefits of systemic corticosteroids.
Funding
UK Research and Innovation (Medical Research Council) and National Institute of Health Research.
In this paper we investigate the risk of privacy leakage through mobile analytics services and demonstrate the ease with which an external adversary can extract individual's profile and mobile applications usage information, through two major mobile analytics services, i.e. Google Mobile App Analytics and Flurry. We also demonstrate that it is possible to exploit the vulnerability of analytics services, to influence the ads served to users' devices, by manipulating the profiles constructed by these services. Both attacks can be performed without the necessity of having an attacker controlled app on user's mobile device. Finally, we discuss potential countermeasures (from the perspectives of different parties) that may be utilized to mitigate the risk of individual's personal information leakage.
Abstract. This paper addresses the important goal of quantifying the threat of linking external records to public Online Social Networks (OSN) user profiles, by providing a method to estimate the uniqueness of such profiles and by studying the amount of information carried by public profile attributes. Our first contribution is to leverage the Ads audience estimation platform of a major OSN to compute the information surprisal (IS) based uniqueness of public profiles, independently from the used profiles dataset. Then, we measure the quantity of information carried by the revealed attributes and evaluate the impact of the public release of selected combinations of these attributes on the potential to identify user profiles. Our measurement results, based on an unbiased sample of more than 400 thousand Facebook public profiles, show that, when disclosed in such profiles, current city has the highest individual attribute potential for unique identification and the combination of gender, current city and age can identify close to 55% of users to within a group of 20 and uniquely identify around 18% of users. We envisage the use of our methodology to assist both OSNs in designing better anonymization strategies when releasing user records and users to evaluate the potential for external parties to uniquely identify their public profiles and hence make it easier to link them with other data sources.
The tremendous popularity of Online Social Networks (OSN) has led to situations, where users have their profiles spread across multiple networks. These partial profiles reflect different user characteristics, depending mainly on the nature of the network, e.g., Facebook's social vs. LinkedIn's professional focus. Combining data gathered by multiple networks may benefit individual users, and the community as a whole, as this could facilitate the provision of more accurate services and recommendations. This paper reports on an exploratory study of the process of making such recommendations using a unique multi-network dataset containing user interests across multiple domains, e.g., music, books, and movies. We represent the data using a graph model and generate recommendations using a set of features extracted from and populated by the model. We assess the contribution of various network-and domain-related features to the accuracy of the recommendations and motivate future work into automated feature selection.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.